Vaginal Cancer - Pipeline Review, H2 2017

Publisher Name :
Date: 30-Nov-2017
No. of pages: 92
Inquire Before Buying

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Cancer - Pipeline Review, H2 2017, provides an overview of the Vaginal Cancer (Oncology) pipeline landscape.

Vaginal cancer is a rare cancer that occurs in vagina. Symptoms includes watery vaginal discharge, a lump or mass in vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Risk factors include age, Smoking, HIV infection and vaginal intraepithelial neoplasia. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vaginal Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Vaginal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vaginal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vaginal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 4, 1 and 1 respectively.

Vaginal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vaginal Cancer (Oncology).

  • The pipeline guide reviews pipeline therapeutics for Vaginal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Vaginal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Vaginal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Vaginal Cancer (Oncology)


Reasons to buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Vaginal Cancer (Oncology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Vaginal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Vaginal Cancer - Pipeline Review, H2 2017

Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Vaginal Cancer - Overview 5
Vaginal Cancer - Therapeutics Development 6
Pipeline Overview 6
Pipeline by Companies 7
Products under Development by Companies 8
Vaginal Cancer - Therapeutics Assessment 9
Assessment by Target 9
Assessment by Mechanism of Action 11
Assessment by Route of Administration 13
Assessment by Molecule Type 15
Vaginal Cancer - Companies Involved in Therapeutics Development 17
ISA Pharmaceuticals BV 17
MedImmune LLC 17
Ology Bioservices Inc 17
Ono Pharmaceutical Co Ltd 18
Oryx GmbH & Co KG 18
Taiwan Liposome Company Ltd 19
Vaginal Cancer - Drug Profiles 20
durvalumab + tremelimumab - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
ISA-101 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
nivolumab - Drug Profile 32
R&D Progress 33
NTO-1151 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
TLC-388 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Vicoryx - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Vaginal Cancer - Dormant Projects 90
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 91
Disclaimer 92

List of Tables

Number of Products under Development for Vaginal Cancer, H2 2017 6
Number of Products under Development by Companies, H2 2017 7
Products under Development by Companies, H2 2017 8
Number of Products by Stage and Target, H2 2017 10
Number of Products by Stage and Mechanism of Action, H2 2017 12
Number of Products by Stage and Route of Administration, H2 2017 14
Number of Products by Stage and Molecule Type, H2 2017 16
Vaginal Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2017 17
Vaginal Cancer - Pipeline by MedImmune LLC, H2 2017 17
Vaginal Cancer - Pipeline by Ology Bioservices Inc, H2 2017 18
Vaginal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 18
Vaginal Cancer - Pipeline by Oryx GmbH & Co KG, H2 2017 18
Vaginal Cancer - Pipeline by Taiwan Liposome Company Ltd, H2 2017 19
Vaginal Cancer - Dormant Projects, H2 2017 90

List of Figures

Number of Products under Development for Vaginal Cancer, H2 2017 6
Number of Products under Development by Companies, H2 2017 7
Number of Products by Targets, H2 2017 9
Number of Products by Stage and Targets, H2 2017 9
Number of Products by Mechanism of Actions, H2 2017 11
Number of Products by Stage and Mechanism of Actions, H2 2017 11
Number of Products by Routes of Administration, H2 2017 13
Number of Products by Stage and Routes of Administration, H2 2017 13
Number of Products by Molecule Types, H2 2017 15
Number of Products by Stage and Molecule Types, H2 2017 15

  • Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Insights 2019, Global and Chinese Scenario
    Published: 21-Jan-2019        Price: US 3000 Onwards        Pages: 150
    Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) industry with a focus on the Chinese market. The report provides key statistics on the market status of the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) manufacturers and is a valuable source of guidance and direction for companies and individ......
  • Global Small Cell Lung Cancer Therapeutics Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2024
    Published: 16-Jan-2019        Price: US 3480 Onwards        Pages: 137
    Lung cancer can be categorized into two types: non-small cell lung cancer and small cell lung cancer. Small cell lung cancer constitutes roughly 10-15 percent of all diagnosed cases of lung cancer. Small cell lung cancer is categorized into two types: small cell carcinoma and combined small cell carcinoma. It can be further classified into two stages: limited-stage small cell lung cancer and extensive-stage small cell lung cancer. Small cell lung cancer is caused by smoking tobacco, or second ha......
  • Peripheral T-Cell Lymphomas (PTCL) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019
    Published: 15-Jan-2019        Price: US 2250 Onwards        Pages: 120
    Introduction DelveInsight's, "Peripheral T-Cell Lymphomas (PTCL) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Peripheral T-Cell Lymphomas (PTCL) . The report includes information of marketed products including their product description, patent details, forecasted sales till 2021 & API manufacturer details by country. Global API Manufacturers of Marketed Products for......
  • Hematopoietic Stem Cell Transplantation - Market Insight, Epidemiology and Market Forecast - 2028
    Published: 15-Jan-2019        Price: US 6250 Onwards        Pages: 100
    DelveInsight's "Hematopoietic Stem Cell Transplantation - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Hematopoietic Stem Cell Transplantation epidemiology and market outlook for the 7MM. Markets Covered - United States - EU5 (Germany, France, Italy, Spain, and the United Kingdom) - Japan Study Period: 2016-2028 Hematopoietic Stem Cell Transplantation Understanding and Treatme......
  • Cervical Dysplasia - Pipeline Insight, 2019
    Published: 15-Jan-2019        Price: US 1250 Onwards        Pages: 50
    "Cervical Dysplasia - Pipeline Insight, 2019" report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Cervical Dysplasia development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Pr......
  • Soft Tissue Sarcoma - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019
    Published: 15-Jan-2019        Price: US 2000 Onwards        Pages: 60
    Introduction DelveInsight's, "Soft Tissue Sarcoma - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Soft Tissue Sarcoma . The report includes information of marketed products including their product description, patent details, forecasted sales till 2021 & API manufacturer details by country. Global API Manufacturers of Marketed Products for Soft Tissue Sarcoma Co......
  • Small Cell Lung Cancer - Epidemiology Forecast to 2028
    Published: 15-Jan-2019        Price: US 3250 Onwards        Pages: 50
    DelveInsight's "Small Cell Lung Cancer - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Small Cell Lung Cancer epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028. Markets Covered - United States - EU5 (Germany, France, Italy, Spain, and the United Kingdom) - Japan Study Period: 2016-2028 Small Cell Lung Cancer Epidemiology The epidem......
  • Soft Tissue Sarcoma - Epidemiology Forecast to 2028
    Published: 15-Jan-2019        Price: US 3250 Onwards        Pages: 50
    DelveInsight's "Soft Tissue Sarcoma - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Soft Tissue Sarcoma epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028. Markets Covered - United States - EU5 (Germany, France, Italy, Spain, and the United Kingdom) - Japan Study Period: 2016-2028 Soft Tissue Sarcoma Epidemiology The epidemiology se......
  • Non-Small Cell Lung Cancer - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019
    Published: 15-Jan-2019        Price: US 2000 Onwards        Pages: 60
    Introduction DelveInsight's, "Non-Small Cell Lung Cancer - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Non-Small Cell Lung Cancer . The report includes information of marketed products including their product description, patent details, forecasted sales till 2021 & API manufacturer details by country. Global API Manufacturers of Marketed Products for Non-Small Cell ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs